On December 10,2020, One World Cannabis filed a Petition under the Insolvency and Rehabilitation Act in the Israeli Haifa District Court AUDIO - 08/31/2020 SHAREHOLDER MEETING (Transcript to Follow) AUDIO - 09/14/2020 SHAREHOLDER MEETING "Transforming cannabis into scientifically proven and clinically approved medical solutions" U.S. Patent 10,603,301 Issued March 31, 2020 - Cannabis-Based Extracts and Topical Formulations for Use in Skin Disorders -- NATIONAL INSTITUTE OF HEALTH CLINICAL TRIALS -- OWC Pharmaceutical Research Corp. (OWCP) A Delaware Corporation since March 6, 2008 11 Anne Frank Street Petah Tikva, Israel 4931113 IR@OWCPHARMA.COM  DELINQUENT SEC REPORTING OWC Pharmaceutical Research Corp. is engaged in the business, through its wholly-owned Israeli subsidiary, One World Cannabis Ltd. ("OWC"), of conducting medical research and clinical trials, in full compliance with all international regulatory protocols, for the development and improvement of strains of medical cannabis specifically designed for the treatment of several illnesses/medical conditions including Multiple Myeloma, Psoriasis, Fibromyalgia, Migraine, and PTSD. Our business plan includes entering into collaborative ventures with major medical centers and highly regarded researchers in Israel and potentially other countries with the goal of developing novel therapeutic methods for the treatment of serious medical conditions with cannabis-based therapies and are conducting pre-clinical investigations and randomized, placebo-controlled trials of cannabis-based compounds and develop unique, condition-specific products. AUTHORIZED 500,000,000 | OUTSTANDING 497,498,338 | FLOAT 206,509,849 | TA Verified 07/01/20 | TA Verified 07/01/20 | 02/09/20 | -- Leadership Team -- ADVISORY BOARD Amir Ohad - Financial Advisor Zvi Riterband - Financial Advisor Dr. Gila Shimoni - Patent Advisor | -- Research --  --Intellectual Property-- ALL PUBLISHED PATENT APPLICATIONS NAME ONE WORLD CANNABIS AS THE ASSIGNEE (OWNER) OWCP's Intellectual Property Portfolio comprises 9 patent families and includes 31 filings in selected domains at various stages from PCT filings, National Phase filings and Continuations in Part (CIP). The National Phase is the second of the two main phases of the Patent Cooperation Treaty (PCT) procedure. It follows the international phase and consists of the processing of the international application before each office of or acting for a contracting state of the PCT that has been designated in the international application. The table below will be updated when the unknown patent families and additional patent applications are identified. RICHTER & SHIMONI OWC's main Patent Agency located in Israel, Germany and Switzerland Richter engages patent lawyers in other domains for filing purposes Dr. Gila Shimoni is primary author/editor of patent application content BROWDY & NEIMARK'S WEBSITE (USPTO) Browdy is OWC's U.S. Intellectual Property Law Firm DENNEMEYER & CO. WEBSITE (AUSPAT) Chronic Pain - Emulsions ACTIONS TAKEN WITHIN PAST 30 DAYS AUSPAT (Australia) (AU) Canadian Intellectual Property Office (CA) Czech IPO (CZ) European Patent Register (EPR) Israel Patent Office (IL) US Patent & Trademark Office (USPTO) WIPO Patentscope (WIPO) To search for USPTO Patent records, enter the Application Number in the search field. View documents under Image File Wrapper tab. To download, check the box in far right column, then click on PDF button above it. Count | Patent Family | Invention Name | Application No. | Filing Date | Filing Domain | Application Published | Last Action | Last Action Date | Patent No. | Patent Granted | 1 | Multiple Myeloma 1 | Novel Cannabinoid Combination Therapies for Multiple Myeloma (MM) | PCT/IL2016/050608 | 06.09.2016 | WIPO | 12.15.2016 | | | | | 2 | | " | 2016276563 | 06.09.2016 | AU | 12.15.2016 | Exam Report #1 | 10.01.2020 | | | 3 | | " | 2988869 | 06.09.2016 | CA | 12.15.2016 | Renewal Fee Paid | 06.09.2020 | | | 4 | | " | 15580718 | 06.09.2016 | USPTO | 05.07.2018 | Non-Final Rejection | 05.12.2020 | | | 5 | | " | 16807035 | 06.09.2016 | EPR | 04.18.2018 | Reply to Examination Report | 08.12.2020 | | | 6 | | " | 256209 | 06.11.2015 | IS | 02.28.2018 | Incoming Correspondence | 04.28.2020 | | | 7 | Multiple Myeloma 2 | Synergistic Use of Cannabis for Treating Multiple Myeloma (MM) | PCT/IL2015/051138 | 11.24.2015 | WIPO | 02.06.2016 | | | | | 8 | | " | 15/863,361 | 11.24.2015 | EPR | 04.10.2017 | Intent to Grant | 11.16.2020 | Intent to Grant | Intent to Grant | 9 | | " | 2015351937 | 11.24.2015 | AU | 02.06.2016 | Examination Report #1 | 03.06.2020 | | | 10 | | " | 2968929 | 11.24.2015 | CA | 02.06.2016 | Renewal Fee Paid | 11.12.2019 | | | 11 | | " | 252504 | 11.26.2014 | IS | 07.31.2017 | Response to Notice of Objection | 03.23.2020 | | | 12 | | " | 15531047 | 11.24.2015 | USPTO | 10.25.2018 | Abandonment | 10.10.2019 | | | 13 | Fibromyalgia | Use of Cannabis to Treat Fibromyalgia, Methods and Compositions Thereof | PCT/IL2016/050498 | 05.11.2016 | WIPO | 11.17.2016 | | | | | 14 | | " | 2016261707 | 05.11.2016 | AU | 11.17.2016 | Examination Report #1 | 06.30.2020 | | | 15 | | " | 2985969 | 05.11.2016 | CA | 11.17.2016 | Renewal Fee Paid | 05.07.2020 | | | 16 | | " | 16792308.5 | 05.11.2016 | EPR | 03.21.2018 | Renewal Fee Paid | 05.09.2020 | | | 17 | | " | 15573687 | 05.11.2016 | USPTO | 05.03.2018 | Abandonment | 02.20.2020 | | | 18 | | " | 255615 | 05.13.2015 | IS | 01.31.2018 | Notice of Objection | 02.17.2020 | | | 19 | Pharmaceutical Emulsions | Preparations of Cannabis Emulsions and Methods Thereof | PCT/IL2016/050289 | 03.17.2016 | WIPO | 09.22.2016 | | | | | 20 | | " | 16764344 | 03.17.2016 | EPR | 01.24.2018 | Renewal Fee Paid | 03.11.2020 | | | 21 | | " | 2982250 | 03.17.2016 | CA | 09.22.2016 | Renewal Fee Paid | 03.09.2020 | | | 22 | | " | 2016231788 | 03.17.2016 | AU | 09.22.2016 | Exam Report #1 | 06.16.2020 | | | 23 | | " | 15708187 | 09.19.2017 | USPTO | 02.15.2018 | Amendments/RFR Forwarded to Examiner | 07.10.2020 | | | 24 | | " | 254598 | 03.19.2015 | IS | 11.20.2017 | Notice of Objection | 01.19.2020 | | | 25 | Migraine | Use of Cannabis to Treat Migraine | PCT/IL2015/051184 | 07.12.2015 | WIPO | 06.16.2016 | | | | | 26 | | " | 15533684 | 06.07.2017 | USPTO | 10.11.2018 | Abandonment | 07.11.2019 | | | 27 | | " | EP15863361 | 11.24.2015 | EPR | 04.10.2017 | Deemed Withdrawn | 10.26.2018 | | | 28 | Sexual Function | Novel Condom Comprising Cannabis Derived Compositions for Enhancement of Sexual Pleasure and Decrease of Erectile Dysfunction Symptoms | PCT/IL2015/051220 | 16.12.2015 | WIPO | 06.23.2016 | | | | | 29 | | " | 15536738 | 16.12.2015 | USPTO | 12.28.2017 | Final Rejection | 07.22.2020 | | | 30 | | " | EP15869472 | 16.12.2015 | EPR | 06.23.2016 | Deemed Withdrawn | 07.27.2018 | | | 31 | | " | 2971144 | 12.17.2014 | CA | 06.23.2016 | Renewal Fee Paid | 12.02.2019 | | | 32 | Skin Disorders | Use of Cannabis to Treat Psoriasis* | PCT/IL2015/051234 | 12.21.2015 | WIPO | 06.30.2016 | Deemed Withdrawn | 06.22.2018 | | | 33 | Skin Disorders | Cannabis-Based Extracts and Topical Formulations for Use in Skin Disorders | 2015101908 | 12.21.2015 | AU | 06.30.2016 | GRANTED | | 2015101908 | 11.08.2017 | 34 | | " | 253066 | 12.21.2014 | IS | 08.31.2017 | Notice of Objection | 04.03.2020 | | | 35 | | " | 15629230 | 06.21.2017 | USPTO | 02.15.2018 | GRANTED | | 10,603,301 | 03.31.2020 | 36 | | " | 2971197 | 06.20.2017 | CA | 12.20.2018 | Renewal Fee Paid | 06.19.2020 | | | 37 | | " | 17178303 | 06.28.2017 | EPR | 12.26.2018 | Extension of Time | 10.13.2020 | | | 38 | Skin Disorders | Hemp extracts and topical preparations for use in skin disorders | 2017-33913 | 7.14.2017 | CZ | 10.31.2018 | GRANTED | | | 01.01.2019 | *The Psoriasis agreement with Sheba Academic Medical Center provides that all intellectual property that is conceived during the course of the research is to be jointly owned by Sheba and One World Cannabis. |